Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NO-CUT: Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
NCT03565029Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jun 2018
- Primary completion
- Oct 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in rectal cancer, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Started Jun 2018; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03565029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565029.